Authored by Maria Dzialo, PhD, Associate Director, Medical Strategy, Inizio Evoke research reveals the growing pressures facing oncologists as they navigate rapid advances in cancer treatment and clinical decision-making.
Oncology innovation is accelerating, bringing new therapies, biomarkers and increasingly complex treatment pathways. But what does this progress mean for the healthcare professionals tasked with translating scientific breakthroughs into patient care?
Our latest white paper, Chasing the Fourth Wave: The human cost of keeping pace, explores the hidden challenges of oncology innovation, drawing on proprietary research with oncologists across six countries.
Key findings reveal the growing burden on oncologists
71% say the effort required to stay current with oncology advances and translate them into treatment decisions has increased over the past five years.
56% report that keeping pace extends into their personal time or creates additional pressure.
81% rapidly implement relevant advances in their own practice, compared with just 54% reporting rapid implementation across the wider healthcare system.
The findings reveal a critical insight: oncologists are successfully adapting to innovation, but that success comes at a human cost.
For pharmaceutical companies, this presents an opportunity to rethink oncology engagement – moving beyond providing more information to delivering more relevant, intuitive and actionable support.
Rooted in our Health More Human® philosophy, the research highlights how a more intuitive, relevant, and human-centered approach to oncology engagement can reduce complexity, better support healthcare professionals, and help bring innovation into clinical practice.
Read the full white paper here.
Interested in hearing more? Connect with us here.